首页> 外文期刊>Pain. >Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database.
【24h】

Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database.

机译:服用阿片类药物的疼痛患者的合并症和医疗服务的利用:来自保险索赔数据库的数据。

获取原文
获取原文并翻译 | 示例
           

摘要

We used a large medical insurance claims database to identify three groups: chronic opioid use (>180 therapeutic days, N=3726); acute opioid use (<10 therapeutic days, N=37,108); and a non-opioid group (N=337,366) who filed at least one insurance claim but none for opioids. Our results showed that although chronic opioid users represented only 0.65% of the total population, they filed 4.56% of all insurance claims, used 45% of all opioid analgesics and had much more physical and psychiatric co-morbidity than the acute opioid or non-opioid samples. Women were substantially over-represented (>63%) in the chronic pain group and used a much greater share of all medical services than males, especially as they grew older. Although our data suggest that chronic pain is optimally managed in a multidisciplinary patient- and gender-specific treatment plan, this was rarely the case with internists being the primary, and often only, physician seen. Moreover, our data suggest that opioids were often used for conditions in which they are generally not indicated (e.g. arthritis and headaches) or contraindicated by co-existing physical ailments (COPD). Finally, we conclude that adherence to the WHO analgesic ladder and other pain treatment guidelines was relatively infrequent: first, opioid extended release preparations which are ideally suited for chronic pain were used only in one in four patients; and, second, the selection of a weak (propoxyphene, codeine, and tramadol) or strong opioid (e.g. morphine and oxycodone) seemed to be driven by numerous factors not necessarily related to the intensity or duration of pain.
机译:我们使用大型医疗保险理赔数据库来识别三类:长期使用阿片类药物(> 180个治疗日,N = 3726);急性使用阿片类药物(<10个治疗日,N = 37,108);非阿片类药物(N = 337,366),他们至少提交了一份保险索赔,但没有针对阿片类药物提出索赔。我们的结果表明,尽管慢性阿片类药物使用者仅占总人口的0.65%,但他们提交了所有保险索赔的4.56%,使用了所有阿片类镇痛药的45%,并且比急性阿片类药物或非阿片类药物具有更高的身体和精神病合并症阿片样物质。在慢性疼痛组中,女性的比例过高(> 63%),并且在所有医疗服务中使用的份额比男性要多得多,尤其是随着年龄的增长。尽管我们的数据表明,在多学科的针对患者和性别的治疗计划中可以最佳地控制慢性疼痛,但内科医师是主要且通常仅见于医师的情况很少。此外,我们的数据表明,阿片类药物通常用于通常不适应症(例如关节炎和头痛)或因并存身体疾病(COPD)禁忌的疾病。最后,我们得出结论,很少有人遵守WHO的止痛阶梯和其他疼痛治疗指南:首先,仅适用于四分之一的患者使用了最适合慢性疼痛的阿片类药物缓释制剂;其次,选择弱的(丙氧芬,可待因和曲马多)或强的阿片类药物(例如吗啡和羟考酮)似乎是由许多因素驱动的,这些因素不一定与疼痛的强度或持续时间有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号